Context

Founded over 14 years ago, GeNeuro develops new treatments for multiple sclerosis (MS), Type 1 diabetes and other potential human endogenous retrovirus-mediated diseases.

The company leverages the biology of human endogenous retroviruses (HERVs) to stop potential key causal factors associated with these disorders. The HERV field is a new frontier pioneered by GeNeuro since 2006, based on 15 years of R&D at Institut Mérieux and INSERM.

In November 2019, GeNeuro and the Karolinska Institutet/Academic Specialist Center of Stockholm agreed to launch a new clinical study of GeNeuro’s flagship product Temelimab in MS. Karolinska will conduct a single-centre study of Temelimab in patients with non-active progressive MS (without relapses). First results are expected at the end of 2021.

This capital raise will be sufficient to cover clinical studies and GeNeuro’s operating costs until the first results of Karolinska study.

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. GeNeuro is based in Geneva, Switzerland and has R&D facilities in Lyon, France. It has 24 employees and rights to 17 patent families protecting its technology.

Discover GeNeuro

Olivier Garnier

Investment Banking

Pierre Kiecolt-Wahl

Equity Capital Markets

Sandrine Cailleteau

Investment Banking

Hervé Ronin

Investment Banking

Falk Müller-Veerse

Investment Banking

Eric Le Berrigaud

Equity & Research

Phil Walker

Investment Banking

Dominic Wilson

Equity Sales

Vincent Meunier

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center